Women tend to develop hypertension later as they transition into menopause, and during and after menopause the development of hypertension in women is independent of age and body mass index (BMI) but is related to menopause itself. One of the mechanisms of hypertension development in postmenopausal women is believed to be the lack of estrogen leading to vasoconstriction due to both reninangiotensin- aldosterone (RAA)-sensitive and sodium-sensitive pathways. Nowadays, we have many medications of antihypertensive therapy, including angiotensin converting enzyme (ACE) and inhibitor and angiotensin receptor blocker (ARB) in addition to diuretics, beta-blockers, calcium channel blockers. The present review summarizes gender differences in the effects of ARB on blood pressure lowering and cardiovascular outcomes from the published reports of large-scaled, randomized clinical trials and its substudy on sexspecific difference. Many antihypertensive drugs have been developed, and the benefit of blood pressure lowering therapy for the prevention of cardiovascular disease would be expected not only in men but also in women as indicated in the large-scaled clinical studies with ARB.
Keywords: Angiotensin receptor blocker (ARB), Blood pressure lowering, Cardiovascular disease, Gender, Sex-difference, Large-scaled randomized study, Renin-angiotensin-aldosteron (RAA) system, Angiotensin, Renin, Hypertension, SYMPHONY, Androgens, vasopressor, antihypertensive, losartan, amlodipine, angina, NYHA, diastolic, Val-HeFT, non-Hispanic
Rights & PermissionsPrintExport